N206100253 53 61002 N20 N20-61002-53 Csii  NSOP about Details Rotary Switch Cam Other Business & Industrial


  1. Home
  2. N206100253 53 61002 N20 N20-61002-53 Csii  NSOP about Details Rotary Switch Cam
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Details about   NSOP Csii N20-61002-53 N20 61002 53 N206100253 Rotary Cam Switch
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Brand:

Csii

MPN:

N20-61002-53

UPC:

Does Not Apply




published on tue nov 09 2021

N206100253 53 61002 N20 N20-61002-53 Csii  NSOP about Details Rotary Switch Cam Other Business & Industrial

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

N206100253 53 61002 N20 N20-61002-53 Csii  NSOP about Details Rotary Switch Cam Other Business & Industrial

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS